Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (61-70 of 317) with videos related to

Pageof 32
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2020
Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology ConferencesEmily A Simons, Derek E Smith, Dexiang Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 16, 2016
A Primer on Health Economic Evaluations in Thoracic OncologyMelanie D Whittington, Adam J Atherly, Gregary T Bocsi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2011
Finding ALK-positive lung cancer: what are we really looking for?D Ross Camidge, Fred R Hirsch, Marileila Varella-Garcia, et al.
Clinical Lung Cancer|May 26, 2022
Quantifying The Medical Impact of A Missed Diagnosis of Non-Small Cell Lung Cancer on Chest ImagingD Ross Camidge, Divneet Mandair, Rustain Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2020
Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy DeliveryChad G Rusthoven, D Ross Camidge, Tyler P Robin, et al.
Rare Tumors|November 17, 2025
Durable response with mutation-guided <i>ALK</i> inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case reportSumra S Chaudhry, D Ross Camidge, Michael R Clay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2026
Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung CancersD Ross Camidge, William J Phillips, Raphael A Nemenoff, et al.
Translational Lung Cancer Research|January 13, 2023
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case seriesRao Mushtaq, Alexis B Cortot, Oliver Gautschi, et al.
Clinical Lung Cancer|December 23, 2018
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose BrigatinibMandy R Sakamoto, Justin M Honce, Deborah L Lindquist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2026
A Response to the Letter to the Editor: Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 TargetsD Ross Camidge, William J Phillips, Raphael A Nemenoff, et al.
Pageof 32

Showing results (61-70 of 317) with videos related to

Sort By:
Pageof 32
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2020
Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology ConferencesEmily A Simons, Derek E Smith, Dexiang Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 16, 2016
A Primer on Health Economic Evaluations in Thoracic OncologyMelanie D Whittington, Adam J Atherly, Gregary T Bocsi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2011
Finding ALK-positive lung cancer: what are we really looking for?D Ross Camidge, Fred R Hirsch, Marileila Varella-Garcia, et al.
Clinical Lung Cancer|May 26, 2022
Quantifying The Medical Impact of A Missed Diagnosis of Non-Small Cell Lung Cancer on Chest ImagingD Ross Camidge, Divneet Mandair, Rustain Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2020
Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy DeliveryChad G Rusthoven, D Ross Camidge, Tyler P Robin, et al.
Rare Tumors|November 17, 2025
Durable response with mutation-guided <i>ALK</i> inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case reportSumra S Chaudhry, D Ross Camidge, Michael R Clay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2026
Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung CancersD Ross Camidge, William J Phillips, Raphael A Nemenoff, et al.
Translational Lung Cancer Research|January 13, 2023
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case seriesRao Mushtaq, Alexis B Cortot, Oliver Gautschi, et al.
Clinical Lung Cancer|December 23, 2018
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose BrigatinibMandy R Sakamoto, Justin M Honce, Deborah L Lindquist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2026
A Response to the Letter to the Editor: Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 TargetsD Ross Camidge, William J Phillips, Raphael A Nemenoff, et al.
Pageof 32